APA (7th ed.) Citation

Mali, N., Tang, Y., Mali, S., Sun, X., Zhang, L., & Fu, P. (2025). Nafamostat mesylate in renal replacement therapy: Balancing efficacy with emerging risks of hyperkalemia. Renal Failure, 47(1), 1. https://doi.org/10.1080/0886022X.2025.2587496

Chicago Style (17th ed.) Citation

Mali, Niroj, YouLi Tang, Saroj Mali, Xiankun Sun, Ling Zhang, and Ping Fu. "Nafamostat Mesylate in Renal Replacement Therapy: Balancing Efficacy with Emerging Risks of Hyperkalemia." Renal Failure 47, no. 1 (2025): 1. https://doi.org/10.1080/0886022X.2025.2587496.

MLA (9th ed.) Citation

Mali, Niroj, et al. "Nafamostat Mesylate in Renal Replacement Therapy: Balancing Efficacy with Emerging Risks of Hyperkalemia." Renal Failure, vol. 47, no. 1, 2025, p. 1, https://doi.org/10.1080/0886022X.2025.2587496.